This MS drug switch means fewer relapses in studyPublished: 30 November 2022 People with multiple sclerosis (MS) who switched from Gilenya (fingolimod) experienced fewer relapses than those who changed to Tysabri (natalizumab) or Mavenclad (cladribine) in a new study. The research included data from 1,045 patients from 26 countries. Each